James E. Flynn 13D and 13G filings for Catalyst Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-13 08:57 am Sale | 2024-12-31 | 13G | Catalyst Pharmaceuticals, Inc. CPRX | James E. Flynn | 3,133,011 2.630% | -3,096,623 (-49.71%) | Filing |
| 2024-11-14 09:55 am Sale | 2024-09-30 | 13G | Catalyst Pharmaceuticals, Inc. CPRX | James E. Flynn | 6,229,634 5.220% | -2,659,267 (-29.92%) | Filing |
| 2024-02-12 5:31 pm Purchase | 2023-12-31 | 13G | Catalyst Pharmaceuticals, Inc. CPRX | James E. Flynn | 8,888,901 8.340% | 3,004,453 (+51.06%) | Filing |
| 2023-02-10 09:28 am Sale | 2022-12-31 | 13G | Catalyst Pharmaceuticals, Inc. CPRX | James E. Flynn | 5,884,448 5.650% | -176,043 (-2.90%) | Filing |
| 2022-11-14 4:45 pm Purchase | 2022-11-04 | 13G | Catalyst Pharmaceuticals, Inc. CPRX | James E. Flynn | 6,060,491 5.820% | 6,060,491 (New Position) | Filing |